First experience with JenaValve™: a single-centre cohort"

V J Nijenhuis, M J Swaans, V Michiels, T de Kroon, R H Heijmen, J M Ten Berg

Research output: Contribution to journalArticle

5 Citations (Scopus)


AIMS: Since the introduction of transcatheter aortic valve implantation (TAVI), newer generation and novel devices such as the retrievable JenaValve™ have been developed. We evaluated the procedural and 6-month results of our first experience with implantation of the JenaValve™.

METHODS AND RESULTS: From June 2012 to December 2013, 24 consecutive patients (mean age 80 ± 7 years, 42 % male) underwent an elective transapical TAVI with the JenaValve™. Device success was 88 %. The mortality rate was 4 % at 30 days and 31 % at 6 months. TAVI reduced the mean transvalvular gradient (44.2 ± 11.1 mmHg vs. 12.3 ± 4.3 mmHg, p < 0.001) and increased the mean aortic valve area (0.8 3 ± 0.23 to 1.70 ± 0.44 cm(2)). A mild paravalvular leakage (PVL) occurred in 4 patients (18 %) and a moderate PVL in 1 patient (4 %). Mean New York Heart Association Functional Class improved from 2.9 ± 0.5 to 2.0 ± 0.8 at 30 days.

CONCLUSION: TAVI using the JenaValve™ prosthesis seems adequate and safe in this first experience cohort.

Original languageEnglish
Pages (from-to)35-41
Number of pages7
JournalNetherlands Heart Journal
Issue number1
Publication statusPublished - Jan 2015


  • Journal Article

Fingerprint Dive into the research topics of 'First experience with JenaValve™: a single-centre cohort"'. Together they form a unique fingerprint.

Cite this